Global Bulk Pricing Trends for 3-[1-(Dimethylamino)ethyl]phenol in 2026
- Market Outlook: Stabilization of bulk price expected through 2026 due to optimized manufacturing process capabilities.
- Technical Specs: High industrial purity grades available with full COA documentation for regulatory compliance.
- Procurement: Strategic sourcing from a certified global manufacturer ensures supply chain security and competitive rates.
The pharmaceutical intermediate market is undergoing significant shifts as we approach 2026, particularly for key compounds used in neurodegenerative disease treatments. Among these, 3-[1-(Dimethylamino)ethyl]phenol stands out as a critical precursor. Procurement managers and chemical buyers must understand the nuanced factors driving valuation beyond simple spot pricing. This analysis provides a technical and commercial overview of the wholesale landscape, focusing on yield optimization, regulatory adherence, and volume-based costing structures.
Factors Influencing Wholesale Costs: Purity, Volume, and Regulatory Compliance
The cost structure for phenolic amines is heavily dependent on the specified industrial purity levels required for downstream synthesis. Standard commercial grades often hover around 95% purity, but pharmaceutical applications frequently demand stricter controls on impurities and isomeric ratios. The molecular formula C10H15NO and molecular weight of 165.236 g/mol define the baseline, yet the separation of enantiomers such as Phenol 3-[(1S)-1-(dimethylamino)ethyl]- and Phenol 3-[(1R)-1-(dimethylamino)ethyl]- can significantly alter production costs.
Buyers evaluating the bulk price must consider the complexity of the manufacturing process. Routes that offer higher stereo-selectivity typically incur higher operational expenses but reduce downstream purification costs. For instance, achieving high enantiomeric excess for 3-[(1R)-1-(Dimethylamino)ethyl]phenol requires specialized catalytic steps. Consequently, suppliers who can demonstrate robust quality control systems and consistent batch-to-batch reproducibility often command a premium, which is justified by reduced risk in the final drug substance production.
Regulatory compliance also plays a pivotal role in pricing. Materials not listed on specific inventories, such as the TSCA inventory in certain regions, may require additional testing or documentation, impacting lead times and costs. A comprehensive COA (Certificate of Analysis) is non-negotiable for GMP-compliant supply chains. It verifies not only chemical identity but also residual solvent levels and heavy metal content, ensuring the material meets international pharmacopeia standards.
Technical Specifications and Market Availability
Understanding the technical baseline is essential for accurate budgeting. The following table outlines the standard specifications typically encountered in the global market for this intermediate. Note that availability often fluctuates based on raw material sourcing for the phenol backbone and dimethylamine derivatives.
| Parameter | Specification | Commercial Notes |
|---|---|---|
| Product Name | 3-[1-(Dimethylamino)ethyl]phenol | Primary Intermediate |
| CAS Number | 105601-04-5 | Verify batch specific |
| Molecular Formula | C10H15NO | Standard Composition |
| Molecular Weight | 165.236 g/mol | Calculation Basis |
| Purity Grade | ≥ 95% to ≥ 98% | Higher purity increases cost |
| Availability | Contact for Availability | Subject to production schedule |
| Pricing Model | Contact for Price (POA) | Volume-dependent tiers |
When evaluating potential partners, it is crucial to assess their technical capability to handle chiral separations if your application requires specific isomers like 3-[(1S)-1-(Dimethylamino)ethyl]phenol. The ability to scale these processes without compromising yield is a key differentiator between trading companies and actual production facilities. Buyers should request sample batches to validate the synthesis route compatibility with their own downstream processes before committing to large volume contracts.
For detailed technical documentation regarding the synthesis route and specific impurity profiles, direct consultation with the manufacturing technical team is recommended. This ensures that the material integrates seamlessly into your existing workflow without requiring extensive re-validation.
How to Request Custom Quotations from Certified Manufacturers
Securing competitive pricing for 2026 requires proactive engagement with suppliers. The market has shifted towards long-term agreements rather than spot purchases to mitigate supply chain volatility. When requesting a quotation, specify your required tonnage, packaging preferences (e.g., drums vs. IBCs), and destination port. This allows the supplier to calculate logistics and tariffs accurately.
As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. specializes in providing high-quality pharmaceutical intermediates with a focus on consistency and regulatory support. Partnering with an established entity like NINGBO INNO PHARMCHEM CO.,LTD. ensures access to reliable production capacity and transparent communication regarding lead times. They offer tailored solutions for bulk procurement, ensuring that the bulk price reflects the volume commitment while maintaining strict quality standards.
In conclusion, the pricing landscape for 3-[1-(Dimethylamino)ethyl]phenol in 2026 will be defined by the balance between purity requirements and supply chain reliability. By focusing on technical specifications, verifying regulatory status, and establishing relationships with certified manufacturers, procurement teams can secure favorable terms. Prioritizing suppliers who offer comprehensive technical support and validated manufacturing processes will ultimately reduce total cost of ownership and ensure uninterrupted production of final pharmaceutical products.